

PCT

WORLD INTELLECTUAL PROP
International B

INTERNATIONAL APPLICATION PUBLISHED UNDER



(51) International Patent Classification ⁶:

C12N 15/86, 7/00, 15/11, A61K 35/76

A1

(11) Lr

WO 9607748A1

(43) International Publication Date:

14 March 1996 (14.03.96)

(21) International Application Number: PCT/EP95/03445

(22) International Filing Date: 1 September 1995 (01.09.95)

(30) Priority Data:

1017/94

2 September 1994 (02.09.94) DK

(71) Applicant (for all designated States except US): GSF-FORSCHUNGSZENTRUM FÜR UMWELT UND GESUNDHEIT GMBH [DE/DE]; Ingolstädter Landstrasse 1, Neuherberg, D-85764 Oberschleissheim (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GÜNZBURG, Walter, Henry [GB/DE]; Mitterfeldstrasse 11, D-85229 Ainhofen (DE). SALLER, Robert, Michael [DE/DE]; Juttastrasse 22, D-80636 München (DE).

(74) Agent: BEHNISCH, Werner; Friedrichstrasse 31, D-80801 München (DE).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).


Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NON SELF-INACTIVATING, EXPRESSION TARGETED RETROVIRAL VECTORS

Construction of a U3 minus BAG-vector (MLV)



(57) Abstract

The present invention relates to a retroviral vector undergoing promoter conversion comprising a 5'LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and a 3'LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region. Said retroviral vector undergoes promoter conversion and is useful as a gene transfer vehicle for targeted gene therapy.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NON SELF-INACTIVATING, EXPRESSION TARGETED RETROVIRAL VECTORS

The present invention relates to retroviral vectors including a vector which undergoes promoter conversion (ProCon vector). The vector system is useful as a gene transfer vehicle for targeted gene therapy.

Background of the Invention

The use of retroviral vectors for gene therapy has received much attention and currently is the method of choice for the transferral of therapeutic genes in a variety of approved protocols both in the USA and in Europe (Kotani *et al.*, 1994). However most of these protocols require that the infection of target cells with the retroviral vector carrying the therapeutic gene occurs in vitro, and successfully infected cells are then returned to the affected individual (Rosenberg *et al.*, 1992; for a review see Anderson, 1992). Such ex vivo gene therapy protocols are ideal for correction of medical conditions in which the target cell population can be easily isolated (e.g. lymphocytes). Additionally the ex vivo infection of target cells allows the administration of large quantities of concentrated virus which can be rigorously safety tested before use.

Unfortunately, only a fraction of the possible applications for gene therapy involve target cells that can be easily isolated, cultured and then reintroduced. Additionally, the complex technology and associated high costs of ex vivo gene therapy effectively preclude its disseminated use world-wide. Future facile and cost-effective gene therapy will require an in vivo approach in which the viral vector, or cells producing the viral vector, are directly administered to the patient in the form of an injection or simple implantation of retroviral vector producing cells.

This kind of in vivo approach, of course, introduces a variety of new problems. First of all, and above all, safety considerations have to be addressed. Virus will be produced, possibly from an implantation of virus producing cells, and there will be no opportunity to precheck the produced virus. It is important to be aware of the finite risk

involved in the use of such systems, as well as trying to produce new systems that minimize this risk.

Retroviral vector systems consist of two components (Fig. 1):

1) the retroviral vector itself is a modified retrovirus (vector plasmid) in which the genes encoding for the viral proteins have been replaced by therapeutic genes and marker genes to be transferred to the target cell. Since the replacement of the genes encoding for the viral proteins effectively cripples the virus it must be rescued by the second component in the system which provides the missing viral proteins to the modified retrovirus.

The second component is:

2) a cell line that produces large quantities of the viral proteins, however lacks the ability to produce replication competent virus. This cell line is known as the packaging cell line and consists of a cell line transfected with a second plasmid carrying the genes enabling the modified retroviral vector to be packaged.

To generate the packaged vector, the vector plasmid is transfected into the packaging cell line. Under these conditions the modified retroviral genome including the inserted therapeutic and marker genes is transcribed from the vector plasmid and packaged into the modified retroviral particles (recombinant viral particles). This recombinant virus is then used to infect target cells in which the vector genome and any carried marker or therapeutic genes becomes integrated into the target cell's DNA. A cell infected with such a recombinant viral particle cannot produce new vector virus since no viral proteins are present in these cells. However the DNA of the vector carrying the therapeutic and marker genes is integrated in the cell's DNA and can now be expressed in the infected cell.

The essentially random integration of the proviral form of the retroviral genome into the genome of the infected cell (Varmus, 1988) led to the identification of a number of cellular proto-oncogenes by virtue of their insertional activation (Varmus, 1988; van

Lohuizen and Bems, 1990). The possibility that a similar mechanism may cause cancers in patients treated with retroviral vectors carrying therapeutic genes intended to treat other pre-existent medical conditions has posed a recurring ethical problem. Most researchers would agree that the probability of a replication defective retroviral vector, such as all those currently used, integrating into or near a cellular gene involving in controlling cell proliferation is vanishingly small. However it is generally also assumed that the explosive expansion of a population of replication competent retrovirus from a single infection event, will eventually provide enough integration events to make such a phenotypic integration a very real possibility.

Retroviral vector systems are optimized to minimize the chance of replication competent virus being present. However it has been well documented that recombination events between components of the retroviral vector system can lead to the generation of potentially pathogenic replication competent virus and a number of generations of vector systems have been constructed to minimize this risk of recombination (reviewed in Salmons and Günzburg, 1993).

A further consideration when considering the use of in vivo gene therapy, both from a safety stand point and from a purely practical stand point, is the targeting of retroviral vectors. It is clear that therapeutic genes carried by vectors should not be indiscriminately expressed in all tissues and cells, but rather only in the requisite target cell. This is especially important if the genes to be transferred are toxin genes aimed at ablating specific tumour cells. Ablation of other, nontarget cells would obviously be very undesirable.

A number of retroviral vector systems have been previously described that should allow targeting of the carried therapeutic genes (Salmons and Gunzburg, 1993). Most of these approaches involve either limiting the infection event to predefined cell types or using heterologous promoters to direct expression of linked heterologous therapeutic or marker genes to specific cell types. Heterologous promoters are used which should drive expression of linked genes only in the cell type in which this promoter is normally active. These promoters have previously been inserted, in combination with the marker or

therapeutic gene, in the body of the retroviral vectors, in place of the *gag*, *pol* or *env* genes.

The retroviral Long Terminal Repeat (LTR) flanking these genes carries the retroviral promoter, which is generally non-specific in that it can drive expression in many different cell types (Majors, 1990). Promoter interference between the LTR promoter, and heterologous internal promoters, such as the tissue specific promoters described above has been reported. Additionally, it is known that retroviral LTRs harbor strong enhancers that can, either independently, or in conjunction with the retroviral promoter, influence expression of cellular genes near the site of integration of the retrovirus. This mechanism has been shown to contribute to tumorigenicity in animals (van Lohuizen and Bems). These two observations have encouraged the development of Self-Inactivating-Vectors (SIN) in which retroviral promoters are functionally inactivated in the target cell (PCT WO94/29437). Further modifications of these vectors include the insertion of promoter gene cassettes within the LTR region to create double copy vectors (PCT. WO 89/11539). However, in both these vectors the heterologous promoters inserted either in the body of the vector, or in the LTR region are directly linked to the marker/therapeutic gene.

The previously described SIN vector mentioned above carrying a deleted 3'LTR (PCT WO94/29437) utilize in addition a strong heterologous promoter such as that of Cytomegalovirus (CMV), instead of the retroviral 5'LTR promoter (U3-free 5'LTR) to drive expression of the vector construct in the packaging cell line. A heterologous polyadenylation signal is also included in the 3'LTR (PCT WO94/29437).

The object of the present invention is the construction of a novel retroviral vector which can be used as a safe gene transfer vehicle for targeted gene therapy with a reduced probability to undergo recombination with the packaging construct. This novel vector carries heterologous promoter and/or regulatory elements in the 3'LTR which, after infection become duplicated and translocated to the 5'LTR in the target cell, eventually controlling expression of marker/therapeutic genes, not directly linked to the promoter, but rather inserted into the body of the vector. This vector does not undergo self-inactivation -

but instead promoter exchange, giving rise to the name ProCon for Promoter Conversion.

Since Promoter Conversion does not result in Self-Inactivation, the retroviral vector will be transcriptionally active in the target cell. However both LTRs will consist to a large extent of heterologous promoter/enhancer sequences in the target cell. This will reduce the likelihood of the integrated vector in the target cell being subject to the same inactivation over long periods as has been described for conventional vectors (Xu *et al.*, 1989) and also will reduce the chance of recombination with endogenous retroviral sequences to generate potentially pathogenic replication competent virus, increasing the safety of the system.

In this invention the 5'LTR of the retroviral vector construct is not modified, and expression of the viral vector in the packaging cells is driven by the normal retroviral U3 promoter. Normal retroviral polyadenylation is allowed, and no heterologous polyadenylation signals are included in the 3'LTR. This is important for the development of *in vivo* gene therapy strategies, since the normal physiological regulation of the virus, through the normal viral promoter, and possibly also involving the normal viral control of polyadenylation, will prevail over long periods *in vivo* whilst the packaging cells are producing recombinant virus.

A further modification of this novel retroviral vector foresees the inclusion of cellular sequences instead of the heterologous promoter and/or regulatory elements. This should allow higher selectivity for site specific recombination with cellular sequences to target the integration of retroviral vectors to particular sites in the host cell genome (Saller, 1994).

To achieve the foregoing and other objects, the invention provides a retroviral vector undergoing promoter conversion comprising a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and a 3' LTR region comprising a completely or partially deleted U3 region wherein said

deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region.

Said polylinker sequence carries at least one unique restriction site and contains preferably at least one insertion of a heterologous DNA fragment. Said heterologous DNA fragment is preferably selected of regulatory elements and promoters, preferably being target cell specific in their expression, but may also be a DNA fragment with no regulatory function.

Said heterologous DNA fragment is preferably homologous to one or more cellular sequences. The regulatory elements and promoters are preferably regulatable by transacting molecules.

Further objects, features and advantages will be apparent from the following description of preferred embodiments of the invention.

The target cell specific regulatory elements and promoters are selected from one or more elements of the group consisting of Whey Acidic Protein (WAP), Mouse Mammary Tumour Virus (MMTV), β -lactoglobulin and casein specific regulatory elements and promoters, pancreas specific regulatory elements and promoters including carbonic anhydrase II and β -glucokinase regulatory elements and promoters, lymphocyte specific regulatory elements and promoters including immunoglobulin and MMTV lymphocytic specific regulatory elements and promoters and MMTV specific regulatory elements and promoters conferring responsiveness to glucocorticoid hormones or directing expression to the mammary gland. Said regulatory elements and promoters regulate preferably the expression of at least one of the coding sequences of said retroviral vector. The LTR regions are selected from at least one element of the group consisting of LTRs of Murine Leukaemia Virus (MLV), Mouse Mammary Tumour Virus (MMTV), Murine Sarcoma Virus (MSV), Simian Immunodeficiency Virus (SIV), Human Immunodeficiency Virus (HIV), Human T-cell Leukaemia Virus (HTLV), Feline Immunodeficiency Virus (FIV), Feline Leukaemia Virus (FELV), Bovine Leukaemia Virus (BLV) and Mason-Pfizer-Monkey virus (MPMV).

The retroviral vector is based preferably either on a BAG vector (Price *et al.*, 1987) or an LXS vector (Miller and Rosman, 1989).

The coding sequence is preferably selected from one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumour genes, cytokine genes.

Said marker and therapeutic genes are preferably selected from one or more elements of the group consisting of β -galactosidase gene, neomycin gene, Herpes Simplex Virus thymidine kinase gene, puromycin gene, cytosine deaminase gene, hygromycin gene, secreted alkaline phosphatase gene, guanine phosphoribosyl transferase (gpt) gene, alcohol dehydrogenase gene and hypoxanthine phosphoribosyl transferase (HPRT) gene.

Another embodiment of the invention envisages the alteration or partial deletion of at least one retroviral sequence required for integration of retroviruses.

In a further embodiment of the invention a retroviral vector system is provided comprising a retroviral vector as described above as a first component and a packaging cell line harbouring at least one retroviral or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.

The packaging cell line harbours retroviral or recombinant retroviral constructs coding for those retroviral proteins which are not encoded in said retroviral vector. The packaging cell line is preferably selected from an element of the group consisting of psi-2, psi-Crypt, psi-AM, GP+E-86, PA317 and GP+envAM-12, or of any of these supertransfected with recombinant constructs allowing expression of surface proteins from other enveloped viruses.

Another embodiment of the invention involves the use of a packaging cell line harbouring a recombinant retroviral construct defective in integrase function.

After introducing the retroviral vector of the invention as described above in a retroviral packaging cell line and infection of a target cell, as described above, a retroviral provirus is provided wherein said polylinker and any sequences inserted in said polylinker in the 3'LTR become duplicated during the process of reverse transcription in the infected target cell and appear in the 5'LTR as well as in the 3'LTR of the resulting provirus.

The invention includes also mRNA of a retroviral provirus according to the invention and any RNA resulting from a retroviral vector according to the invention.

A further embodiment of the invention provides non-therapeutical method for introducing homologous and/or heterologous nucleotide sequences into human or animal cells *in vitro* and *in vivo* comprising transfecting a packaging cell line of a retroviral vector system according to the invention with a retroviral vector according to the invention and infecting a target cell population with recombinant retroviruses produced by the packaging cell line. The nucleotide sequences are selected from one or more elements of the group consisting of genes or parts of genes encoding for proteins, regulatory sequences and promoters.

The retroviral vector, the retroviral vector system and the retroviral provirus as well as RNA thereof is used for producing a pharmaceutical composition for gene therapy in mammals including humans. Furthermore, they are used for targeted integration in homologous cellular sequences.

Promoter conversion

The present invention uses the principle of promoter conversion typical for retroviruses.

The retroviral genome consists of an RNA molecule with the structure R-U5-gag-pol-env-U3-R (Fig. 2). During the process of reverse transcription, the U5 region is

uplicated and placed at the right hand end of the generated DNA molecule, whilst the U3 region is duplicated and placed at the left hand end of the generated DNA molecule (Fig. 2). The resulting structure U3-R-U5 is called LTR (Long Terminal Repeat) and is thus identical and repeated at both ends of the DNA structure or provirus (Varmus, 1988). The U3 region at the left hand end of the provirus harbours the promoter (see below). This promoter drives the synthesis of an RNA transcript initiating at the boundary between the left hand U3 and R regions and terminating at the boundary between the right hand R and U5 region (Fig. 2). This RNA is packaged into retroviral particles and transported into the target cell to be infected. In the target cell the RNA genome is again reverse transcribed as described above.

According to the invention a retroviral vector is constructed in which the right- hand U3 region is altered (Fig. 3), but the normal left-hand U3 structure is maintained (Fig. 3); the vector can be normally transcribed into RNA utilizing the normal retroviral promoter located within the left-hand U3 region (Fig. 3). However the generated RNA will only contain the altered right-hand U3 structure. In the infected target cell, after reverse transcription, this altered U3 structure will be placed at both ends of the retroviral structure (Fig. 3).

If the altered region carries a polylinker (see below) instead of the U3 region then any promoter, including those directing tissue specific expression such as the WAP promoter (see below) can be easily inserted. This promoter will then be utilized exclusively in the target cell for expression of linked genes carried by the retroviral vector. Alternatively or additionally DNA segments homologous to one or more cellular sequences can be inserted into the polylinker for the purposes of gene targeting, by homologous recombination(see below).

According to the invention the term "polylinker" is used for a short stretch of artificially synthesized DNA which carries a number of unique restriction sites allowing the easy insertion of any promoter or DNA segment. The term "heterologous" is used for any combination of DNA sequences that is not normally found intimately associated in nature.

Gene expression is regulated by promoters. In the absence of promoter function a gene will not be expressed. The normal MLV retroviral promoter is fairly unselective in that it is active in most cell types (Majors, 1990). However a number of promoters exist that show activity only in very specific cell types. Such tissue-specific promoters will be the ideal candidates for the regulation of gene expression in retroviral vectors, limiting expression of the therapeutic genes to specific target cells.

In the packaging cell line the expression of the retroviral vector is regulated by the normal unselective retroviral promoter contained in the U3 region (Fig. 3). However as soon as the vector enters the target cell promoter conversion occurs, and the therapeutic or marker gene, e.g. b-galactosidase are expressed from a tissue specific promoter of choice introduced into the polylinker (Fig. 3). Not only can virtually any tissue specific promoter be included in the system, providing for the selective targeting of a wide variety of different cell types, but additionally, following the conversion event, the structure and properties of the retroviral vector no longer resembles that of a virus. This, of course, has extremely important consequences from a safety point of view, since ordinary or state of the art retroviral vectors readily undergo genetic recombination with the retroviral packaging construct and/or endogenous retroviruses to produce potentially pathogenic viruses. Promoter conversion (ProCon) vectors do not resemble retroviruses because they no longer carry U3 retroviral promoters after conversion thus reducing the possibility of genetic recombination.

The retroviral promoter structure is carried within the U3 region of the LTR. LTRs carry signals that allow them to integrate into the genome of the target cell. The integration of retroviral proviruses can also contribute to pathogenic changes (van Lohuizen and Bems, 1990). In one embodiment of the invention ProCon vectors can carry modified LTRs that no longer carry the signals required for integration. Again this increases the potential safety of these vector systems.

Gene Targeting

According to another aspect of the present invention the retroviral vector is used for targeted integration into the target cell. The integration of the proviral DNA version of the retroviral genome into the target cell is a major advance to the use of retroviruses as vectors when compared to other viruses such as adenoviruses, since it allows long term stable expression of transferred genes. However the random nature of this integration event also poses a major disadvantage to the use of retroviral vectors since it raises the possibility of insertional (in)activation of cellular tumour suppressor genes or proto-oncogenes and thus tumour induction (van Lohuizen and Berns, 1990).

Homologous recombination has been successfully used to target the integration of transfected or microinjected DNA to specific DNA loci and is routinely used in the construction of "knock-out" transgenic mice or animals (reviewed in Capecchi, 1989; Bradley *et al.*, 1992; Morrow and Kucherlapati, 1993). Unfortunately the efficiency of DNA transfer by such purely physical methods is extremely low. In contrast retroviral mediated gene transfer is very efficient, almost 100% of a population of cells being infectable. A combination of retroviral gene transfer with homologous recombination should allow the construction of an ideal system for locus targeted integration.

We have investigated the feasibility of introducing long homologous pieces of DNA into retroviral vectors in different locations to promote integration by homologous recombination (Saller, 1994). Both gene conversion and homologous recombination have been evaluated. Using a cell line carrying a single copy of the HSV-tk gene as a target we have been able to disrupt the target at frequencies 15 fold higher than previously reported by others (Ellis and Bernstein, 1989). Cloning of the recombined fragments of DNA has revealed the presence of both target tk sequence and retroviral vector (Saller, 1994).

For targeted integration DNA segments homologous to cellular sequences are inserted into the polylinker of the ProCon vectors. After infection of the target cell and

reverse transcription, these sequences will appear at the 5' terminal end of the provirus. Terminal homologies have been shown to favour homologous recombination (Bradley, 1991) to isogenic cellular sequences (Bradley, 1991). Infection of target cells which carry mutated versions of the homologous sequence should result in the recombination and thus repair of the mutated sequence. Either just the homologous sequences will recombine into the cellular genome, or the complete vector will be inserted (Saller, 1994). Not only has this vector class potential for use in gene repair, it can also be utilized to direct the integration of retroviral vectors carrying therapeutic genes to specific loci in the genome which are known not to harbour active genes. This will reduce considerably the possibility of insertional activation or inactivation as described above, and will thus contribute to the safety of the use of retroviral vectors.

The following examples will illustrate the invention further. These examples are however in no way intended to limit the scope of the present invention as obvious modifications will be apparent, and still other modifications and substitutions will be apparent to anyone skilled in the art.

The recombinant DNA methods employed in practicing the present invention are standard procedures, well known to those skilled in the art, and described in detail, for example, in "Molecular Cloning" (Sambrook et al. 1989) and in "A Practical Guide to Molecular Cloning" (Perbal, 1984).

Brief description of the drawings referred to in the following examples:

- Fig. 1; Retroviral vector system
- Fig. 2: Retroviral genome, reverse transcription
- Fig. 3: ProCon principle
- Fig. 4: PCR analysis, MLV probe
- Fig. 5: PCR analysis, MMTV probe
- Fig. 6: β -galactosidase expression in infected NIH and EF43 cells

- Fig. 7: β -galactosidase expression in infected primary mammary glands cells from a pregnant mouse
- Fig. 8: β -galactosidase expression after virus injection into mammary gland and the skin of a pregnant Balb/c mouse
- Fig. 9: β -galactosidase expression in infected mammary tumour cells
- Fig. 10: Targeted integration of a retroviral vector by homologous recombination

Example 1

Mammary gland specific expression after infection with ProCon Vectors carrying mammary specific promoters.

In the murine leukemia virus (MLV) retroviral vector known as BAG (Price et al., 1987) the β -galactosidase gene is driven by the promiscuous (i.e. non-tissue specific) MLV promoter in the U3 region of the LTR (Fig. 3). According to the present invention a derivative of the BAG vector has been constructed in which the MLV promoter (U3) located within the 3'LTR (Fig. 3) has been deleted and replaced with a polylinker, said polylinker allowing the facile introduction of heterologous promoters. The BAG vector lacking the U3 is expressed from the MLV promoter (U3) within the 5'LTR when introduced into a packaging cell line. As a result of the rearrangements occurring in the retroviral genome during its life cycle, following infection of its target cell, the polylinker will be duplicated at both ends of the retroviral genome as described above. Thereby a retroviral vector can be constructed in which the expression of the β -galactosidase gene of BAG will be controlled by any heterologous promoter inserted into the polylinker in the target cell (Fig. 3).

According to the principle set forth above the following specific promoters have been inserted into the polylinker region of the modified BAG vector:

Several subregions of the Mouse Mammary Tumour Virus (MMTV) promoter including a region that confers responsiveness to glucocorticoid hormones and a region containing an element that directs expression to the mammary gland.

The Whey Acidic Protein (WAP) promoter. This promoter controls the expression of WAP so that it is only produced in the mammary glands of pregnant and lactating rodents.

The control of the β -galactosidase gene expression by promoters inserted into the polylinker has been validated by infection studies using the constructed MMTV and WAP retroviral vectors to infect various cells.

To produce retroviral vector particles, the MMTV and WAP ProCon vectors have been transfected into the packaging cell line GP+E86 (Markowitz et al., 1988). After selection for neomycin resistance, which is encoded by the vector, stable populations and clones of recombinant ProCon virus producing cells were obtained. Virus containing supernatant from these populations was used to infect a mouse mammary cell line EF43 (Günzburg *et al.*, 1988) as well as a mouse fibroblast cell line (Jainchill *et al.*, 1969). Four days after infection the target cells were lysed and quantitative β -galactosidase assay revealed no expression in either cell type infected by the WAP carrying ProCon vectors and good expression in both cell types from the MMTV carrying ProCon vector (Fig. 6). This result is in accordance with the WAP promoter only functioning *in vivo* during late pregnancy and lactation and not in most simple *in vitro* mammary cell culture systems as represented by the EF43 cells. To investigate whether the WAP carrying ProCon vectors would be active in a complex primary mammary derived cell culture system, primary organoids from 8-10 day pregnant mice (Fig. 7) or from mammary tumours (Fig. 9) were taken into culture and infected with the supernatant from the same stably transfected population of transfected cell lines. Both ProCon vectors carrying the WAP and the MMTV promoter fragments were active in these primary cells (Fig. 7) and mammary tumour derived cells (Fig. 9) as demonstrated by β -galactosidase activity.

To investigate whether the WAP and MMTV carrying ProCon vectors were active *in vivo* and whether the expression of β -galactosidase was limited to the mammary gland *in vivo*, recombinant ProCon virus containing medium was injected *in situ* into the mammary glands or skin of 8-10 day pregnant mice. Five days later the mice were sacrificed, cell extracts prepared and a β -galactosidase assay performed. Both the WAP and MMTV fragment carrying ProCon vectors were expressed only in the pregnant mammary gland and not in the skin (cf M and S in Fig. 8). Thus *in vivo* the regulatory elements from both promoters limit expression to the mammary gland

whereas in vitro the regulatory elements from the WAP promoter retain their strict tissue specificity but those of MMTV do not.

These ProCon vectors carrying tissues specific promoters and regulatory elements will be useful for directing the expression of therapeutic genes to predefined cell types, tissues and organs. Potential therapeutic genes include melittin, which has anti-HIV and anti-tumour effects, and genes which prime cells for death including the thymidine kinase, guanine phosphoribosyltransferase and cytosine deaminase genes, cytochrome P450 as well as genes involved in cell cycle regulation such as SDI/WAF-1/CIP-1.

Example 2

Validation of promoter conversion in cells infected with a ProCon vector that originally carried the MMTV promoter in the 3'LTR.

A ProCon vector carrying the promoter region from mouse mammary tumour virus (MMTV) was transfected into a packaging cell line and the resultant recombinant vector particles used to infect an established human bladder carcinoma cell line (EJ). Infected cell clones were selected in medium carrying the neomycin analog G418 (since the vector carries a neomycin resistance gene driven from an internal SV40 promoter). DNA was prepared from one of the infected clones and nontransfected parental EJ cells and used for Polymerase Chain Reactions (PCR). The PCRs were performed using one of two primers that specifically recognise and bind to MMTV sequences (A, B in Figs. 4 & 5) or the MLV R region (C in Fig. 4) of the LTR together with a primer located within the marker gene (Figs. 4 & 5). Since the marker gene primer is only located down stream of the MMTV (or MLV R region) sequence if promoter conversion has occurred, a positive PCR signal obtained with the MMTV primers in combination with the marker gene primer is indicative of this. In Fig. 4 the PCR products using primers A, B or C are shown after hybridization to a labelled fragment from the MLV sequence, verifying that all three PCR products are of MLV origin. The size of the fragments verifies that promoter conversion has occurred. Fig. 5 shows the PCR products using primer A or B and hybridized to an MMTV specific probe, again verifying that promoter conversion has occurred.

Example 3

Construction of ProCon Vectors for targeted integration.

Using the same BAG vector described in Example 1 above, a retroviral vector can be constructed in which a DNA sequence with homology to a cellular sequence can be inserted into the LTR. The resulting vector can be used to target the integration of either the homologous sequence inserted into the vector or the whole or part of the vectors into the homologous sequence present in the host cell genome.

According to the principle set forth above, a fragment of the thymidine kinase (tk) gene of herpes simplex virus (HSV) has been inserted into the polylinker region of the modified BAG vector (tk mutant in Fig. 10, Saller, 1994).

A cell line has also been established that has no functional copy of the mammalian tk gene and instead carries one copy of the HSV-tk gene (Saller, 1994). This cell line has been infected with the tk carrying BAG vector and cells that have undergone disruption of the HSV-tk gene have been selected (Fig. 10).

The above examples have illustrated the principles and consequences of the promoter conversion vectors provided by the present invention.

References

Anderson, W.F. 1992. Human gene therapy. *Science* 256: 808-813.

Bradley, A. 1991. Modifying the mammalian genome by gene targeting. *Curr. Opin. Biotechnol.* 2: 823-829.

Bradley, A., P. Hasty, A. Davis, and R. Ramirez-Solis. 1992. Modifying the mouse: design and desire. *Bio/technology* 10: 534-539.

Capecchi, M.R. 1989. Altering the genome by homologous recombination. *Science* 244: 1288-1292.

Ellis, J. and A. Bernstein. 1989. Gene Targeting with Retroviral Vectors
Recombination by Gene Conversion into Regions of Nonhomology. *Mol. Cell. Biol.* 9:
1621-1627.

Emerman, M. and H.M. Temin. 1986. Comparison of promoter suppression in avian
and murine retrovirus vectors. *Nucl. Acids Res.* 14: 9381-9396.

Günzburg, W.H., B. Salmons, A. Schlaeffli, S. Moritz-Legrand, W. Jones, N.H.
Sarkar, and R. Ullrich. 1988. Expression of the oncogenes *mil* and *ras* abolishes the
in vivo differentiation of mammary epithelial cells. *Carcinogenesis* 9: 1849-1856.

Jainchill, J.L., S.A. Anderson, and G.J. Todaro. 1969. Murine sarcoma and leukaemia
viruses: assay using clonal lines of contact-inhibited mouse cells. *J. Virol* 4: 549-553.

Kotani, H., P.B. Newton, S. Zhang, Y.L. Chiang, E. Otto, L. Weaver, R.M. Blaese,
W.F. Anderson, and G.J. McGarrity. 1994. Improved methods of retroviral vector
transduction and production for gene therapy. *Human Gene Therapy* 5: 19-28.

Majors, J. 1990. The structure and function of retroviral long terminal repeats, *Curr.*
Tops. In Micro. Immunol. 157: 49-92.

Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. *J. Virol.* 62: 1120-1124.

Miller, A.D. and G.J. Rossman. 1989. Improved retroviral vectors for gene transfer and expression. *Biotechniques* 7: 980-990.

Morrow, B. and R. Kucherlapati. 1993. Gene targeting in mammalian cells by homologous recombination. *Current Opinion in Biotechnology* 4: 577-582.

Perbal, B. 1984. *A Practical Guide to Molecular Cloning*, John Wiley & Sons.

Price, J., D. Turner, and C. Cepko. 1987. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. *Proc. Natl. Acad. Sci. USA* 84: 156-160.

Rosenberg, S.A., Anderson, W.F., Blaese, R.M. et al. 1992. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. *Hum. Gene Ther.* 3: 75-90.

Saller, R.M. 1994 Design von locus- und gewebespezifischen retroviralen Vektoren fuer eine in vivo Gentherapie. Doctoral thesis, Ludwigs-Maximilians University Munich, Germany.

Salmons, B. and W.H. Günzburg. 1993. Targeting of retroviral vectors for gene therapy. *Human Gene Therapy* 4: 129-141.

Sambrook, J., E.F. Fritsch and T. Maniatis. 1989. *Molecular Cloning*. Cold Spring Harbor Laboratory Press, New York, USA

van Lohuizen and Berns. 1990. Tumorigenesis by slow-transforming retroviruses - an update. *Biochim. Biophys. Acta*, 1032: 213-235.

Varmus, H. 1988. Retroviruses. Science 240: 1427-1435.

Xu, L., J.-K. Yee, J.A. Wolff and T. Friedmann. 1989. Factors Affecting Long-Term Stability of Moloney Murine Leukemia Virus-Based Vectors. Virology 171: 331-341.

CLAIMS

1. A retroviral vector undergoing promoter conversion comprising a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and
a 3' LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region.
2. A retroviral vector according to claim 1 comprising a 5' LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and
a 3' LTR region comprising a completely deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region.
3. A retroviral vector according to claim 1, wherein said polylinker sequence carries at least one unique restriction site.
4. A retroviral vector according to claim 3, wherein said polylinker sequence contains at least one insertion of a heterologous DNA fragment.
5. A retroviral vector according to claim 4, wherein said heterologous DNA fragment is selected from one or more elements of the group consisting of regulatory elements and promoters.
6. A retroviral vector according to claim 5, wherein said regulatory elements and promoters are target cell specific in their expression.
7. A retroviral vector according to claim 6, wherein said target cell specific regulatory elements and promoters are selected from one or more elements of the group consisting of WAP, MMTV, b-lactoglobulin and casein specific regulatory elements and promoters, pancreas specific regulatory elements and promoters

including carbonic anhydrase II and b-glucokinase regulatory elements and promoters, lymphocyte specific regulatory elements and promoters including immunoglobulin and MMTV lymphocytic specific regulatory elements and promoters and MMTV specific regulatory elements and promoters conferring responsiveness to glucocorticoid hormones or directing expression to the mammary gland.

8. A retroviral vector according to anyone of claims 5 to 7, wherein said regulatory elements and promoters regulate the expression of at least one of the coding sequences of said retroviral vector.

9. A retroviral vector according to anyone of claims 1 to 8, wherein said LTR regions are selected from at least one element of the group consisting of LTRs of MLV, MMTV, MSV, SIV, HIV, HTLV, FIV, FeLV, BLV and MPMV.

10. A retroviral vector according to anyone of claims 1 to 9, wherein said retroviral vector is a BAG vector.

11. A retroviral vector according to anyone of claims 1 to 10, wherein said coding sequence is selected from one or more elements of the group consisting of marker genes, therapeutic genes, antiviral genes, antitumour genes, cytokine genes.

12. A retroviral vector according to claim 11, wherein said marker or therapeutic gene is selected from one or more elements of the group consisting of b-galactosidase gene and neomycin gene, Herpes Simplex Virus, thymidine kinase gene, puromycin gene, cytosine deaminase gene, hygromycin gene, secreted alkaline phosphatase gene, guanine phosphoribosyl transferase (gpt) gene, alcohol dehydrogenase gene and hypoxanthine phosphoribosyl transferase (HPRT) gene.

13. A retroviral vector according to anyone of claims 1 to 12, wherein at least one of said coding sequences for a retroviral protein is altered or at least partially deleted.

14. A retroviral vector according to anyone of claims 1 to 13, wherein retroviral sequences involved in integration of retroviruses are altered or at least partially deleted.
15. A retroviral vector according to anyone of claims 1 to 14, wherein said heterologous DNA fragment is homologous to one or more cellular sequences or a part thereof.
16. A retroviral vector according to anyone of claims 1 to 15, wherein said regulatory elements are regulatable by transacting molecules.
17. A retroviral vector system comprising a retroviral vector according to anyone of claims 1 to 16 as a first component; and
a packaging cell line harbouring at least one retroviral or recombinant retroviral construct coding for proteins required for said retroviral vector to be packaged.
18. A retroviral vector system according to claim 17 wherein the packaging cell line harbours retroviral or recombinant retroviral constructs coding for those retroviral proteins which are not encoded in said retroviral vector according to anyone of claims 1 to 16.
19. A retroviral vector system according to claim 17 or 18 wherein the packaging cell line is selected from the group consisting of psi-2, psi-Crypt, psi-AM, GP+E-86, PA317 and GP+envAM-12.
20. A therapeutical or non-therapeutical method for introducing homologous or heterologous nucleotide sequences into human or animal cells *in vitro* and *in vivo* comprising transfecting a packaging cell line of a retroviral vector system according to anyone of claims 17 to 19 with a retroviral vector according to anyone of claims 1 to 16, and infecting a target cell population with said recombinant retroviruses produced by the packaging cell line.

21. A therapeutical or non-therapeutical method according to claim 20, wherein the nucleotide sequences are selected from one or more elements of the group consisting of genes or parts of genes encoding for proteins, regulatory sequences and promoters.
22. A retroviral provirus produced by replicating the retroviral vector of anyone of claims 1 to 16 in a retroviral vector system according to anyone of claims 17 to 19 wherein said polylinker and any sequences inserted in said polylinker in the 3'LTR become duplicated during the process or reverse transcription in the infected target cell and appear in the 5'LTR as well as in the 3'LTR of the resulting provirus.
23. Use of a retroviral vector according to anyone of claims 1 to 16 for producing a pharmaceutical composition for gene therapy in mammals including humans.
24. Use of a retroviral vector system according to anyone of claims 17 to 19 for producing a pharmaceutical composition for gene therapy in mammals including humans.
25. Use of a retroviral provirus according to claim 22 for producing a pharmaceutical composition for gene therapy in mammals including humans.
26. Use of a retroviral vector according to anyone of claims 1 to 16 for targeted integration in said homologous cellular sequences.
27. Use of a retroviral vector system according to anyone of claims 17 to 19 for targeted integration in said homologous cellular sequences.
28. Use of a retroviral provirus according to claim 22 for targeted integration in said homologous cellular sequences.
29. mRNA of a retroviral provirus according to claim 22.
30. RNA of a retroviral vector according to anyone of claims 1 to 16.

31. Recombinant retroviral particle obtained by transfecting a packaging cell line of a retroviral vector system according to anyone of claims 17-19 with a retroviral vector according to anyone of claims 1 to 16, and culturing the cells under suitable conditions.

32. Pharmaceutical composition containing a therapeutically effective amount of a recombinant retroviral particle according to claim 31.

01 / 10




Fig. 2




Fig. 3

Construction of a U3 minus BAG-vector (MLV)





Fig. 4



05 / 10

Fig. 5




Fig. 6







Fig. 7

Fig. 8




**β -gal assay for infected
Mouse Mammary
Tumour Cells**

Fig. 9



10/10

Fig. 10



INTERNATIONAL SEARCH REPORT

International Application No

PC/EP 95/03445

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N7/00 C12N15/11 A61K35/76

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	------------------------------------------------------------------------------------	-----------------------

A	HUMAN GENE THERAPY, vol. 5, no. 6, June 1994 pages 667-677, L.A.COUTURE ET AL. 'Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression' see page 668, right column, paragraph 2 ---	1-32
A	EP,A,0 415 731 (THE WELLCOME FOUNDATION LIMITED) 6 March 1991 see page 6, line 35 - line 44 --- -/--	1-32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 "A" document member of the same patent family

Date of the actual completion of the international search

10 January 1996

Date of mailing of the international search report

24.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International Application No
PC 1/EP 95/03445

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BLOOD, vol. 74, no. 2, 1 August 1989 pages 876-881, R.A.HOCK ET AL. 'Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines' see figure 1 ---	1-32
P,X	BIOLOGICALS, vol. 23, no. 1, March 1995 pages 5-12, W.H.GUNZBURG ET AL. 'Retroviral vectors directed to predefined cell types for gene therapy' see paragraph bridging pages 6 and 7 -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 95/03445

Box I Observations where certain claims were found unsearchable (Continuation of item I of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20, 21
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 20 and 21 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/03445

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0415731	06-03-91	AU-B- 647747	31-03-94
		AU-B- 6199190	07-03-91
		AU-B- 6458794	08-09-94
		CN-A- 1050899	24-04-91
		EP-A- 0657539	14-06-95
		EP-A- 0657540	14-06-95
		EP-A- 0657541	14-06-95
		EP-A- 0690129	03-01-96
		JP-A- 3172189	25-07-91
